HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $26 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 87.8%

Neg 0% Neu 87.8% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and maintains $26 price target.